The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PERSEPHONE: Duration of trastuzumab with chemotherapy in patients with HER2-positive early breast cancer—Six versus twelve months.
Helena Margaret Earl
Consultant or Advisory Role - Roche
Research Funding - Roche
David A. Cameron
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Other Remuneration - Roche
David Miles
No relevant relationships to disclose
Andrew M. Wardley
No relevant relationships to disclose
Emma Ogburn
No relevant relationships to disclose
Anne-Laure Vallier
No relevant relationships to disclose
Shrushma Loi
No relevant relationships to disclose
Louise Hiller
No relevant relationships to disclose
Janet Dunn
No relevant relationships to disclose